This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Pediatric Eye Disease Investigator Group^*

Arch Ophthalmol. 2003;121:1625-1632.

Objective  To assess the psychosocial impact on the child and family of patching and atropine as treatments for moderate amblyopia in children younger than 7 years.

Methods  In a randomized, controlled clinical trial, 419 children younger than 7 years with amblyopic eye visual acuity in the range of 20/40 to 20/100 were assigned to receive treatment with either patching or atropine at 47 clinical sites. After 5 weeks of treatment, a parental quality-of-life questionnaire was completed for 364 (87%) of the 419 patients.

Main Outcome Measure  Overall and subscale scores on the Amblyopia Treatment Index.

Results  High internal validity and reliability were demonstrated for the Amblyopia Treatment Index questionnaire. The overall Amblyopia Treatment Index scores and the 3 subscale scores were consistently higher (worse) in the patching group compared with the atropine-treated group (overall mean, 2.52 vs 2.02, P<.001; adverse effects of treatment: mean, 2.35 vs 2.11, P = .002; difficulty with compliance: mean, 2.46 vs 1.99, P<.001; and social stigma: mean, 3.09 vs 1.84, P<.001, respectively).

Conclusion  Although the Amblyopia Treatment Index questionnaire results indicated that both atropine and patching treatments were well tolerated by the child and family, atropine received more favorable scores overall and on all 3 questionnaire subscales.

^*The authors for the Pediatric Eye Disease Investigator Group are Jonathan M. Holmes, BM, BCh (chair); Roy W. Beck, MD, PhD; Raymond T. Kraker, MSPH; Stephen R. Cole, PhD; Michael X. Repka, MD; Eileen E. Birch, PhD; Joost Felius, PhD; Stephen P. Christiansen, MD; David K. Coats, MD; Marjean T. Kulp, OD. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psychological causes of non-compliance with electronically monitored occlusion therapy for amblyopia
Loudon et al.
Br J Ophthalmol 2009;93:1499-1503.
ABSTRACT | FULL TEXT  

Pharmacological Plus Optical Penalization Treatment for Amblyopia: Results of a Randomized Trial
Pediatric Eye Disease Investigator Group
Arch Ophthalmol 2009;127:22-30.
ABSTRACT | FULL TEXT  

How Much Amblyopia Treatment Is Enough?
Repka
Arch Ophthalmol 2008;126:990-991.
FULL TEXT  

Band-Aids and Amblyopia
Lempert
Arch Ophthalmol 2008;126:145-145.
FULL TEXT  

Current Recommendations for Amblyopia Treatment
Arnoldi
Amer. Orthoptic Jrnl. 2007;57:60-67.
ABSTRACT  

Refractive Surgery in Children: Is It Ready for Prime Time?
Paysse
Amer. Orthoptic Jrnl. 2007;57:79-88.
ABSTRACT  

Long-term visual acuity and its predictors after surgery for congenital cataract: findings of the british congenital cataract study.
Chak et al.
IOVS 2006;47:4262-4269.
ABSTRACT | FULL TEXT  

The timing of patching treatment and a child's wellbeing
Williams et al.
Br J Ophthalmol 2006;90:670-671.
FULL TEXT  

Treatment of Amblyopia in Older Children
Hunter
Arch Ophthalmol 2005;123:557-558.
FULL TEXT  

The Pediatric Eye Disease Investigator Group Report May Be Too Optimistic About Efficacy of Treatment: In Reply
Quinn et al.
Pediatrics 2004;114:1366-1367.
FULL TEXT  

Recent Advances in the Treatment of Amblyopia
Quinn et al.
Pediatrics 2004;113:1800-1802.
FULL TEXT